Dabigatran approaching the realm of heparin-induced thrombocytopenia.
- Author:
Patricia J HO
1
;
Juan A SIORDIA
Author Information
- Publication Type:Review
- Keywords: Dabigatran; Anticoagulation; Heparin-induced thrombocytopenia
- MeSH: Anticoagulants; Antithrombins; Dabigatran*; Heparin, Low-Molecular-Weight; Mortality; Thrombocytopenia*; Thrombosis
- From:Blood Research 2016;51(2):77-87
- CountryRepublic of Korea
- Language:English
- Abstract: Heparin-induced thrombocytopenia (HIT) is a serious, immune mediated complication of exposure to unfractionated or low-molecular-weight heparin. Though rare, it is a condition associated with high morbidity and mortality that requires immediate change to alternative anticoagulants for the prevention of life-threatening thrombosis. The direct thrombin inhibitors lepirudin and argatroban are currently licensed for the treatment of HIT. Dabigatran, a novel oral anticoagulant (NOAC) with a similar mechanism of action and effective use in other indications, has recently been proposed as another therapeutic option in cases of HIT. This review serves as an introduction to using dabigatran for this purpose, detailing the clinical aspects of its administration, evidence of its performance compared to other anticoagulants, and the preliminary reports of HIT successfully treated with dabigatran. As the literature on this develops, it will need to include clinical trials that directly evaluate dabigatran against the other NOACs and current treatment options.
